Zhangping He1, Yanyan Tang1, Chao Qin2. 1. Department of Neurology, First Affiliated Hospital, Guangxi Medical University, No. 22, Shuang Yong Road, Nanning 530021, Guangxi, China. 2. Department of Neurology, First Affiliated Hospital, Guangxi Medical University, No. 22, Shuang Yong Road, Nanning 530021, Guangxi, China. Electronic address: hmdqc6639@163.com.
Abstract
OBJECTIVES: Circulating leukocyte-derived microparticles act as proinflammatory mediators that reflect vascular inflammation. In this study, we examined the hypothesis that the quantity of leukocyte-derived microparticles is increased in patients with ischemic cerebrovascular diseases, and investigated utility of various phenotypes of leukocyte-derived microparticles as specific biomarkers of vascular inflammation injury. Additionally we focused on identifying leukocyte-derived microparticles that may be correlated with stroke severity in acute ischemic stroke patients. METHODS: The plasma concentration of leukocyte-derived microparticles obtained by a series of centrifugations of 76 consecutive patients with ischemic cerebrovascular diseases and 70 age-, sex-, and race-matched healthy controls were determined by flow cytometry. RESULTS: Significantly elevated numbers of leukocyte (CD45+), monocyte (CD14+), lymphocyte (CD4+), granulocyte (CD15+) derived microparticles were found in the plasma samples of patients ischemic cerebrovascular diseases, compared to healthy controls (p<0.05). Furthermore, the plasma levels of CD14+ microparticles were significantly correlated with stroke severity (r=0.355, p=0.019), cerebral vascular stenosis severity (r=0.255, p=0.025) and stroke subtype (r=0.242, p=0.036). No association with stroke was observed for other leukocyte-derived phenotypes. CONCLUSIONS: These results demonstrate that circulating leukocyte-derived microparticles amounts are increased in patients with ischemic cerebrovascular diseases, compared with healthy controls. As proinflammatory mediators, leukocyte-derived microparticles may contribute to vascular inflammatory and the inflammatory process in acute ischemic stroke. Levels of CD14+ microparticles may be a promising biomarker of ischemic severity and outcome of stroke in the clinic.
OBJECTIVES: Circulating leukocyte-derived microparticles act as proinflammatory mediators that reflect vascular inflammation. In this study, we examined the hypothesis that the quantity of leukocyte-derived microparticles is increased in patients with ischemic cerebrovascular diseases, and investigated utility of various phenotypes of leukocyte-derived microparticles as specific biomarkers of vascular inflammation injury. Additionally we focused on identifying leukocyte-derived microparticles that may be correlated with stroke severity in acute ischemic strokepatients. METHODS: The plasma concentration of leukocyte-derived microparticles obtained by a series of centrifugations of 76 consecutive patients with ischemic cerebrovascular diseases and 70 age-, sex-, and race-matched healthy controls were determined by flow cytometry. RESULTS: Significantly elevated numbers of leukocyte (CD45+), monocyte (CD14+), lymphocyte (CD4+), granulocyte (CD15+) derived microparticles were found in the plasma samples of patientsischemic cerebrovascular diseases, compared to healthy controls (p<0.05). Furthermore, the plasma levels of CD14+ microparticles were significantly correlated with stroke severity (r=0.355, p=0.019), cerebral vascular stenosis severity (r=0.255, p=0.025) and stroke subtype (r=0.242, p=0.036). No association with stroke was observed for other leukocyte-derived phenotypes. CONCLUSIONS: These results demonstrate that circulating leukocyte-derived microparticles amounts are increased in patients with ischemic cerebrovascular diseases, compared with healthy controls. As proinflammatory mediators, leukocyte-derived microparticles may contribute to vascular inflammatory and the inflammatory process in acute ischemic stroke. Levels of CD14+ microparticles may be a promising biomarker of ischemic severity and outcome of stroke in the clinic.
Authors: Yonatan Hirsch; Joseph R Geraghty; Cory R Reiter; Eitan A Katz; Conner F Little; Matthew K Tobin; Fernando D Testai Journal: Transl Stroke Res Date: 2022-05-06 Impact factor: 6.829
Authors: Wenche Jy; Ashish K Rehni; Carlos Bidot; Hever Navarro-Quero; Conner R Haase; Sebastian Koch; Yeon S Ahn; Kunjan R Dave Journal: Front Pharmacol Date: 2018-06-11 Impact factor: 5.810
Authors: Jaakko Leskelä; Milla Pietiäinen; Anton Safer; Markku Lehto; Jari Metso; Ernst Malle; Florian Buggle; Heiko Becher; Jouko Sundvall; Armin J Grau; Pirkko J Pussinen; Frederick Palm Journal: PLoS One Date: 2020-02-21 Impact factor: 3.240
Authors: Che Mohd Nasril Che Mohd Nassir; Mazira Mohamad Ghazali; Sabarisah Hashim; Nur Suhaila Idris; Lee Si Yuen; Wong Jia Hui; Haziq Hazman Norman; Chuang Huei Gau; Nanthini Jayabalan; Yuri Na; Linqing Feng; Lin Kooi Ong; Hafizah Abdul Hamid; Haja Nazeer Ahamed; Muzaimi Mustapha Journal: Front Cardiovasc Med Date: 2021-02-24